Harrow, Inc. (HROW) Stock Price & Analysis

Harrow, Inc. (HROW) closed at USD 29.39 on Wednesday, October 28, 2026, up 1.10% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 29.07; the Oct 28, 2026 session ranged USD 28.83–29.74 on volume of 327,012 shares. Market capitalization is $1.10B, with a 52-week range of USD 26.96–54.85 (NGM). Source: Nexqual, retrieved October 29, 2026 at 13:25 UTC.

Also available as compact Markdown for AI agents: nexqual.com/HROW.md

Key facts (HROW)

• Last four reported quarters (through Jun 30, 2026): revenue $276M, net income -$37.2M (-13.5% margin), free cash flow $5.0M (SEC filings).
• Insider open-market sales, last ~7 months: 1 Form 4 filings, $450K; 1 not under a Rule 10b5-1 plan ($450K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 4 Form 4 filings, $469K; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 2.00 on a 1–5 scale) (9 analysts), mean target USD 63 (range 45–88).
• Total return with dividends: 1Y -20.1% vs S&P 500 +13.6%; 5Y +191.3% vs S&P 500 +79.8%.
• Next earnings: 2026-11-09, EPS estimate USD 0.32, revenue estimate $99.1M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (HROW)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (HROW)

P/S 4.0x · EV/Sales 4.8x · P/FCF 219.7x · P/B 72.5x · FCF yield 0.46% · Earnings yield -3.38% · Net debt $208M · EV $1.31B

Insider sales (SEC Form 4, open-market, last ~7 months) (HROW)

0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (HROW)

4 purchases, $469K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (HROW)

Consensus Buy (mean 2.00 on a 1–5 scale), 9 analysts; mean target USD 63 (low 45, high 88).

Rating changes, last 120 days:

Total return (dividends reinvested) (HROW)

HROW earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

HROW recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

HROW revenue by business segment (quarter ended Jun 30, 2026)

HROW revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

HROW suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 2, 2026.

HROW customer concentration

In the period ended Jun 30, 2025, a single direct customer accounted for 10% of revenue, per the company's 10-Q filed Aug 10, 2026. The company does not name it.

HROW company outlook (results filed Aug 10, 2026)

• “The Company encourages Harrow stockholders to review these documents, which provide additional details concerning the historical results and future expectations for the business. “We spent the first half of 2026 building demand and positioning the business to achieve our 2026 and 2027 financial objectives.”
• “Based on what we're seeing across the business today, I remain confident in our ability to deliver our full-year guidance of $350 million to $365 million in revenue and $80 million to $100 million in adjusted EBITDA.””
• “The Company also expects an increasing proportion of VEVYE prescriptions to shift to the commercial channel over the balance of 2026.”
• “(aflibercept biosimilar) expected to further expand the portfolio in 2027.”

Quoted word-for-word from the SEC 8-K results press release.

HROW analyst estimates and revisions

HROW options: expected move

Options price a move of about ±19.2% (±$5.65) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±11.5% on average.

30-day implied volatility 76.1% vs 36.3% realized over the last 30 trading days. Put/call ratio (volume) 0.02. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 13:25 UTC)

Technical Analysis (HROW)

Nexqual's technical model rates HROW "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 13:25 UTC.

Analyst Ratings (HROW)

Wall Street analysts rate HROW "Buy" based on 9 analysts, with a mean price target of USD 63 (range USD 45–88), per Nexqual as of October 29, 2026 at 13:25 UTC.

Earnings (HROW)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 13:25 UTC.

Financials & Fundamentals (HROW)

Source: Nexqual, October 29, 2026 at 13:25 UTC.

Ownership (HROW)

Source: Nexqual, October 29, 2026 at 13:25 UTC.

From Harrow, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• As a potential FDA-approved successor, MELT-300 is a patented, sublingually delivered formulation of a fixed dose of midazolam (3mg) and ketamine (50mg) designed to provide rapid, predictable sedation without the need for intravenous administration.
• We do, however, believe that our drug candidates and drug products could have commercial appeal in international markets, and have engaged distributors and entered into out-licensing arrangements for certain of our products and proprietary formulations in certain non-U.S. markets, including Canada.
• Manufacturers, including us, are required to report average sales price information to the Centers for Medicare & Medicaid Services ("CMS") on a quarterly basis.
• As a condition of approval, the FDA or other regulatory authorities may require further studies, including Phase 4 post-marketing studies, to provide additional data.

Partnerships

• For over a decade, we have partnered with U.S. eyecare professionals to develop a comprehensive portfolio of high-quality products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 13:25 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt